Dr Hughes on the Safety of Asciminib in Ph+ CP-CML

Timothy Hughes, MD, MBBS, FRACP, FRCPA, clinical director, Precision Cancer Medicine Theme at SAHMRI, consultant hematologist, Royal Adelaide Hospital, discusses safety data from the phase 3 ASC4FIRST trial (NCT04971226) evaluating asciminib (Scemblix) vs investigator-selected TKIs in patients with newly diagnosed, Philadelphia chromosome (Ph)–positive, chronic-phase chronic myeloid leukemia (CP-CML).

 showed that the study met its co-primary end points. At week 48, asciminib (n = 201) produced a major molecular response (MMR) rate of 67.7% vs 49.0% investigator-selected TKIs (n = 204; difference, 18.9%; 95% CI, 9.6%-28.2%; 

 < .001). For patients treated with asciminib (n = 101) or an investigator-selected TKI (n = 102) within the imatinib stratum, the MMR rates at week 48 were 69.3% and 40.2%, respectively (difference, 29.6%; 95% CI, 16.9%-42.2%; 

The MMR rate at week 48 for second-generation asciminib (n = 100) or a second-generation TKI (n = 102) was a key secondary end point. The MMR rate at week 48 was 66.0% for asciminib and 57.8% for second-generation TKIs (difference, 8.2%; 95% CI, –5.1% to 21.5%).

Regarding safety, Hughes explains that a significant unmet need exists around the use of second or third-generation TKIs in patients with Ph+ CP-CML. Efficacy benefits of other agents in this class have historically been diminished by associated toxicities, he says. Hughes notes that during ASC4FIRST, asciminib exhibited a high potency with a toxicity profile that is as good or better than that of imatinib (Gleevec). Given the efficacy and safety data derived for asciminib, this could represent a beneficial treatment that does not feature the same level of safety concerns observed for other second- or third-generations TKIs, he says.

Videos

Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.



Timothy Hughes, MD, MBBS, FRACP, FRCPA discussed findings from the ASC4FIRST trial comparing asciminib vs investigator-selected TKIs in CP-CML.

Timothy Hughes, MD, MBBS, FRACP, FRCPA, clinical director, Precision Cancer Medicine Theme at SAHMRI, consultant hematologist, Royal Adelaide Hospital discusses efficacy findings from the phase 3 ASC4FIRST trial (NCT04971226) evaluating asciminib (Scemblix) vs investigator-selected TKIs in patients with newly diagnosed Philadelphia chromosome (Ph)–positive chronic-phase chronic myeloid leukemia (CP-CML).

The study randomly assigned patients at least 18 years of age with Ph-positive CP-CML to receive asciminib or investigator’s choice of TKI. Both arms included an imatinib (Gleevec) stratum and a second-generation TKI stratum.

 showed that the study met its co-primary end points. At week 48, patients treated with asciminib (n = 201) experienced a major molecular response rate (MMR) of 67.7% compared with 49.0% for patients treated with any investigator-selected TKI (n = 204; difference, 18.9%; 95% CI, 9.6%-28.2%; 

 < .001). Regarding the second primary end point of MMR at week 48 for patients treated with asciminib (n = 101) or an investigator-selected TKI (n = 102) within the imatinib stratum, the MRRs were 69.3% and 40.2%, respectively (difference, 29.6%; 95% CI, 16.9%-42.2%; 

Notably, MMR at week 48 for patients who received second-generation asciminib (n = 100) or a second-generation TKI (n = 102) was a key secondary end point. The MMR at week 48 was 66.0% for asciminib and 57.8% for second-generation TKIs (difference, 8.2%; 95% CI, –5.1% to 21.5%). Hughes notes that there was a numerical difference that was not statistically significant for this end point; however, he notes that the study was not powered to measure the statistical significance of this end point.

In his presentation, Hughes concluded by noting that these data could support asciminib as the therapy of choice in the first-line setting for patients with Ph–positive CP-CML, and longer-term follow-up will further elucidate the potential benefit of this therapy in this setting.

Timothy Hughes, MD, MBBS, FRACP, FRCPA discussed findings from the ASC4FIRST trial comparing asciminib vs investigator-selected TKIs in CP-CML.



Timothy Hughes, MD, MBBS, FRACP, FRCPA

Articles

Dr Hughes on the Safety of Asciminib in Ph+ CP-CML

Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML